Human-derived normal mesenchymal stem/stromal cells in anticancer therapies

Journal of Cancer

Volumn 8, Issue 1, 2017, Pages 85-96

  Zhang, Cheng ^a,b,c   Yang, Shi Jie ^a,b,c   Wen, Qin ^a,b,c   Zhong, Jiang F ^b,c   Chen, Xue Lian ^b,c   Stucky, Andres ^b,c   Press, Michael F ^d   Zhang, Xi ^a,b,c  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Mesenchymal stem stromal cells; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER CELL LINE; CANCER THERAPY; CELL CONTACT; CELL INTERACTION; CELL THERAPY; CELL TRANSDIFFERENTIATION; CENTRAL NERVOUS SYSTEM TUMOR; DIGESTIVE SYSTEM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FEMALE GENITAL TRACT CANCER; FIBROBLAST; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; MOLECULAR BIOLOGY; NONHUMAN; PARACRINE SIGNALING; RESPIRATORY TRACT CANCER; TUMOR MICROENVIRONMENT; URINARY TRACT CANCER;

EID: 85009754962     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.16792     Document Type: Article

References (80)

1. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21: 309-22.
2. Gao L, Chen XH, Zhang X, et al. Contribution of SDF-1/CXCR4 axis on proliferation of megakaryocyte co-cultured with human umbilical cord blood-derived stromal cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009; 17: 412-6.
3. Yuan Y, Lu X, Chen X, et al. Jagged1 contributes to the drug resistance of jurkat cells in contact with human umbilical cord derived mesenchymal stem cells. Oncol Lett. 2013; 6: 1000-6.
4. Liu Y, Chen XH, Si YJ, et al. Reconstruction of hematopoietic inductive microenvironment after transplantation of VCAM-1-modified human umbilical cord blood stromal cells. PLoS One. 2012; 7: e31741.
5. Boutter J, Huang Y, Marovca B, et al. Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. Oncotarget. 2014; 5: 11501-12.
6. Zhang Y, Hu K, Hu Y, et al. Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation. Ann Hematol. 2014; 93:1499-508.
7. Yuan Y, Lu X, Chen X, et al. Jagged1 contributes to the drug resistance of jurkat cells in contact with human umbilical cord derived mesenchymal stem cells. Oncol Lett. 2013; 6: 1000-6.
8. Yuan Y, Chen D, Chen X, et al. Human umbilical cord-derived mesenchymal stem cells inhibit proliferation but maintain survival of Jurkat leukemia cells in vitro by activating Notch signaling. Nan Fang Yi Ke Da Xue Xue Bao. 2014; 34: 441-7.
9. Mousavi Niri N, Jaberipour M, Razmkhah M, et al. Mesenchymal stem cells do not suppress lymphoblastic leukemic cell line proliferation. Iran J Immunol. 2009; 6: 186-94.
10. Liang X, Hao L, Chen X, et al. Effects of bone marrow stromal cells and umbilical cord blood-derived stromal cells on daunorubicin-resistant residual Jurkat cells. Transplant Proc. 2010; 42: 3767-72.
11. Tabe Y, Konopleva M, Munsell MF, et al. PML-RARa is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood. 2004; 103: 1815-22.
12. Fonseka M, Ramasamy R, Tan BC, et al. Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) inhibit the proliferation of K562 (human erythromyeloblastoid leukaemic cell line). Cell Biol Int. 2012; 36: 793-801.
13. Yuan Y, Lu X, Tao CL, et al. Forced expression of indoleamine-2, 3-dioxygenase in human umbilical cord-derived mesenchymal stem cells abolishes their anti-apoptotic effect on leukemia cell lines in vitro. In Vitro Cell Dev Biol Anim. 2013; 49: 752-8.
14. Wang H, Zhou J, Xu JJ, et al. Comparison and analysis between CLL-hBMSC and N-hBMSC. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014; 22: 914-9.
15. Tung S, Shi Y, Wong K, et al. PPARa and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 2013; 122:969-80.
16. Secchiero P, Zorzet S, Tripodo C, et al. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One. 2010; 5: e11140.
17. Lin HD, Fong CY, Biswas A, et al. Human Wharton's jelly stem cells, its conditioned medium and cell-free lysate inhibit the growth of human lymphoma cells. Stem Cell Rev. 2014; 10:573-86.
18. Ciavarella S, Caselli A, Tamma AV, et al. A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression. Stem Cells Dev. 2015; 24: 1457-70.
19. Gao L, Zhang C, Zhang X, et al. Human umbilical cord blood-derived stromal cells: A new resource for the proliferation and apoptosis of myeloma cells. Hematology. 2014; 19: 148-57.
20. Goldstein RH, Reagan MR, Anderson K,et al. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res. 2010; 70: 10044-50
21. Iyengar P, Combs TP, Shah SJ, et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and protooncogene stabilization. Oncogene. 2003; 22: 6408-23.
22. Leng L, Wang Y, He N, et al. Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy. Biomaterials. 2014; 35: 5162-70.
23. Ma F, Chen D, Chen F, et al. Human umbilical cord mesenchymal stem cells promote breast cancer metastasis by interleukin-8 and interleukin-6 dependent induction of CD44+/CD24- cells. Cell Transplant. 2015; 24: 2585-99.
24. Li T, Zhao S, Song B, et al. Effects of transforming growth factor β-1 infected human bone marrow mesenchymal stem cells on high- and low-metastatic potential hepatocellular carcinoma. Eur J Med Res. 2015; 20: 56.
25. Li T, Song B, Du X, et al. Effect of bone-marrow-derived mesenchymal stem cells on high-potential hepatocellular carcinoma in mouse models: an intervention study. Eur J Med Res. 2013; 18: 34.
26. Zhao W, Ren G, Zhang L, et al. Efficacy of mesenchymal stem cells derived from human adipose tissue in inhibition of hepatocellular carcinoma cells in vitro. Cancer Biother Radiopharm. 2012; 27: 606-13.
27. Yulyana Y, Ho IA, Sia KC, et al. Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling. Mol Ther. 2015; 23: 746-56.
28. De Boeck A, Pauwels P, Hensen K, et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut. 2013; 62: 550-60.
29. Chen D, Liu S, Ma H, et al. Paracrine factors from adipose-mesenchymal stem cells enhance metastatic capacity through Wnt signaling pathway in a colon cancer cell co-culture model. Cancer Cell Int. 2015; 15: 42.
30. Wang M, Cai J, Huang F, et al. Pre-treatment of human umbilical cord-derived mesenchymal stem cells with interleukin-6 abolishes their growth-promoting effect on gastric cancer cells. Int J Mol Med. 2015; 35: 367-75.
31. Wang Y, Fan H, Zhou B, et al. Fusion of human umbilical cord mesenchymal stem cells with esophageal carcinoma cells inhibits the tumorigenicity of esophageal carcinoma cells. Int J Oncol. 2012; 40: 370-7.
32. Jing W, Chen Y, Lu L, et al. Human umbilical cord blood-derived mesenchymal stem cells producing IL-15 eradicate established pancreatic tumor in syngeneic mice. Mol Cancer Ther. 2014; 13: 2127-37.
33. Shin SH, Kim J, Heo SC, et al. Proteomic identification of betaig-h3 as a lysophosphatidic acid-induced secreted protein of human mesenchymal stem cells: paracrine activation of A549 lung adenocarcinoma cells by betaig-h3. Mol Cell Proteomics. 2012; 11: M111.012385.
34. Matsuzuka T, Rachakatla RS, Doi C, et al. Human umbilical cord matrix-derived stem cells expressing interferon-β gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer. 2010; 70: 28-36
35. Takahara K, Ii M, Inamoto T, et al. Adipose-derived stromal cells inhibit prostate cancer cell proliferation inducing apoptosis. Biochem Biophys Res Commun. 2014; 446:1102-7.
36. Han I, Yun M, Kim EO, et al. Umbilical cord tissue-derived mesenchymal stem cells induce apoptosis in PC-3 prostate cancer cells through activation of JNK and downregulation of PI3K/AKT signaling. Stem Cell Res Ther. 2014; 5: 54.
37. Hsiao WC, Sung SY, Liao CH, et al. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth. Mol Pharm. 2012; 9: 1396-408.
38. Chu Y, Tang H, Guo Y, et al. Adipose-derived mesenchymal stem cells promote cell proliferation and invasion of epithelial ovarian cancer. Exp Cell Res. 2015; 337: 16-27.
39. Klopp AH, Zhang Y, Solley T, et al. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res. 2012; 18: 771-82.
40. Gauthaman K, Yee FC, Cheyyatraivendran S, et al. Human umbilical cord Wharton's jelly stem cell (hWJS) extracts inhibit cancer cell growth in vitro. J Cell Biochem. 2012; 113: 2027-39.
41. Yang C, Lei D, Ouyang W, et al. Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro. Biomed Res Int. 2014; 2014:109389.
42. Rowan BG, Lacayo EA, Sheng M, et al. Human adipose tissue-derived stromal/stem cells promote migration and early metastasis of head and neck cancer xenografts. Aesthet Surg J. 2016; 36: 93-104.
43. Ahn JO, Coh YR, Lee HW, et al. Human adipose tissue-derived mesenchymal cells inhibit melanoma growth in vitro and in vivo. Anticancer Res. 2015; 35: 159-68.
44. Kim YH, Cho SH, Lee SJ, et al. Growth-inhibitory effect of neurotrophin-3-secreting adipose tissue-derived mesenchymal stemcells on the D283-MED human medulloblastoma cell line. J Neurooncol. 2012; 106: 89-98.
45. Wen S, Niu Y, Yeh S, et al. BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts. Int J Oncol. 2015; 47: 719-27.
46. Mishra PJ, Mishra PJ, Humeniuk R, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008; 68: 4331-9
47. Subramanian A, Shu-Uin G, Kae-Siang N, et al. Human umbilical cord Wharton's jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. J Cell Biochem. 2012; 113: 1886-95.
48. Cho JA, Park H, Lim EH, et al. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol. 2012; 40: 130-8.
49. Del Valle PR, Milani C, Brentani MM, et al. Transcriptional profile of fibroblasts obtained from the primary site, lymph node and bone marrow of breast cancer patients. Genet Mol Biol. 2014; 37: 480-9.
50. Dvořánková B, Smetana K Jr, Říhová B, et al. Cancer-associated fibroblasts are not formed from cancer cells by epithelial-to-mesenchymal transition in nu/nu mice. Histochem Cell Biol. 2015; 43: 463-9.
51. Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25: 719-34.
52. Martin FT, Dwyer RM, Kelly J, et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat. 2010; 124: 317-26.
53. Xu Q, Wang L, Li H, et al. Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-β. Int J Oncol. 2012; 41: 959-68.
54. Velpula KK, Dasari VR, Tsung AJ, et al. Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget. 2011; 2: 1028-42.
55. Ye X, Weinberg RA. Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol. Trends Cell Biol. 2015; 25: 675-86.
56. Jose S, Tan SW, Ooi YY, et al. Mesenchymal stem cells exert anti-proliferative effect on lipopolysaccharide-stimulated BV2 microglia by reducing tumour necrosis factor-a levels. J Neuroinflammation. 2014; 11: 149.
57. Johann PD, Vaegler M, Gieseke F, et al. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer. 2010; 10: 501.
58. Barnas JL, Simpson-Abelson MR, Brooks SP, et al. Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors. J Immunol. 2010; 185: 2681-92.
59. Ferrand J, Noël D, Lehours P, et al. Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. PLoS One. 2011; 6: e19569.
60. Xu MH, Gao X, Luo D, et al. EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells. PLoS One. 2014; 9: e87893.
61. Kuhbier JW, Bucan V, Reimers K, et al. Observed changes in the morphology and phenotype of breast cancer cells indirect co-culture with adipose-derived stem cells. Plast Reconstr Surg. 2014; 134: 414-23.
62. Wei HJ, Nickoloff JA, Chen WH, et al. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells. Oncotarget. 2014; 5: 9514-29.
63. Zhang MJ, Sun JJ, Qian L, et al. Human umbilical mesenchymal stem cells enhance the expression of neurotrophic factors and protect ataxic mice. Brain Res. 2011; 1402: 122-31.
64. Widder M, Lutzkendorf J, Caysa H, et al. Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β-integrin-dependent mechanism. Int J Cancer. 2015.
65. Sun B, Yu KR, Bhandari DR, et al. Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation. Cancer Lett. 2010; 296: 178-85.
66. Chan JK, Gnecchi M, Huynh H, et al. Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling. Mol Ther. 2015; 23: 746-56.
67. Zhang XH, Sun Y, Wang ZY, et al. Alterations of connexin 43 expression and SDF-1a secretion of bone marrow mesenchymal stem cells co-cultured with myeloma cells. Zhonghua Xue Ye Xue Za Zhi. 2013; 34: 788-93.
68. Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 2010; 290: 58-67.
69. Menge T, Gerber M, Wataha K, et al. Human mesenchymal stem cells inhibit endothelial proliferation and angiogenesis via cell-cell contact through modulation of the VE-Cadherin/beta-catenin signaling pathway. Stem Cells Dev. 2013; 22: 148-57.
70. Mandel K, Yang Y, Schambach A, et al. Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo. Stem Cells Dev. 2013; 22: 3114-27.
71. Yang S, Wen Q, Liu Y, et al. Increased expression of CX43 on stromal cells promotes leukemia apoptosis. Oncotarget. 2015; 6: 44323-31.
72. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010; 12: 576-8.
73. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012; 7: e47559.
74. Cammarota F, Laukkanen MO. Mesenchymal stem/stromal cells in stromal evolution and cancer progression. Stem cell Int. 2015; 2015: 427350.
75. Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008; 22: 593-9.
76. Zhang C, Zhang X, Chen XH. Cellular mechanism for granulocyte-colony stimulating factor in the prevention of graft-versus-host disease in combined bone marrow and peripheral blood transplantation for hematological malignancies: The composition in collection. Transfus Apher Sci. 2013; 48: 3-9.
77. Zhang C, Zhang X, Chen XH. Granulocyte-colony stimulating factor-mobilized mesenchymal stem cells: A new resource for rapid engraftment in hematopoietic stem cell transplantation. Medical Hypotheses. 2011; 6: 241-3.
78. Glenn JD, Whartenby KA. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World Journal of Stem Cells. 2014; 6: 526-39.
79. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010; 5: e10088.
80. Waterman RS, Henkle SL, Betancourt AM. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One. 2012; 7: e45590.